BrightGene Bio Medical Technology C (688166) — Cash Flow Reinvestment Rate
BrightGene Bio Medical Technology C (688166) has a Cash Flow Reinvestment Rate of 3.77x as of June 2023, reinvesting CN¥100.56 Million (capex CN¥68.06 Million plus investments CN¥-32.50 Million) from operating cash flow of CN¥26.70 Million. Check BrightGene Bio Medical Technology C cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BrightGene Bio Medical Technology C Cash Flow Reinvestment Rate (2016–2024)
Historical reinvestment intensity for BrightGene Bio Medical Technology C across 9 annual periods. Explore cash flow to debt ratio of BrightGene Bio Medical Technology C to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for BrightGene Bio Medical Technology C (2016–2024)
Year-by-year capital reinvestment analysis for BrightGene Bio Medical Technology C. For live market cap and broader valuation context, see BrightGene Bio Medical Technology C (688166) total market value.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.97x | CN¥484.23 Million | CN¥245.56 Million | CN¥257.20 Million | ▼ -54.0% |
| 2023 | 4.28x | CN¥834.53 Million | CN¥194.77 Million | CN¥389.33 Million | ▲ +51.5% |
| 2022 | 2.83x | CN¥880.11 Million | CN¥311.26 Million | CN¥726.73 Million | ▼ -45.8% |
| 2021 | 5.22x | CN¥918.30 Million | CN¥176.08 Million | CN¥909.66 Million | ▲ +41.3% |
| 2020 | 3.69x | CN¥573.73 Million | CN¥155.43 Million | CN¥355.27 Million | ▲ +44.9% |
| 2019 | 2.55x | CN¥156.20 Million | CN¥61.33 Million | CN¥89.54 Million | ▼ -23.5% |
| 2018 | 3.33x | CN¥213.01 Million | CN¥63.99 Million | CN¥112.47 Million | ▼ -35.4% |
| 2017 | 5.15x | CN¥184.24 Million | CN¥35.77 Million | CN¥83.70 Million | ▲ +109.3% |
| 2016 | 2.46x | CN¥73.16 Million | CN¥29.73 Million | CN¥36.58 Million | — |